Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2388
Título : Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders
Creador: García de la Puente S
Nivel de acceso: Open access
Palabras clave : Colesterol - sangre - niño
HDL-Colesterol - sangre - niño
LDL-Colesterol -sangre - niño
Estudios Cruzados - niño
Relación Dosis-Respuesta a Droga - niño
Método Doble Ciego - niño
Hiperlipidemias - complicaciones - niño
Hiperlipidemias - quimoterapia - niño
Hipolipemiantes - efectos adversos - niño
Hipolipemiantes - uso terapéutico - niño
Enfermedades Renales - quimioterapia - niño
Simvastatina - efectos adversos - niño
Simvastatina - uso terapéutico - niño
Resultado del Tratamiento
Triglicéridos - sangre - niño
Cholesterol - blood - child
Cholesterol, HDL - blood - child
Cholesterol, LDL - blood - child Cross-Over Studies - child
Dose-Response Relationship, Drug - child
Double-Blind Method - child
Hyperlipidemias - complications - child
Hyperlipidemias - drug therapy - child
Hypolipidemic Agents - adverse effects - child
Hypolipidemic Agents - therapeutic use - child
Kidney Diseases - drug therapy - child
Simvastatin - adverse effects - child
Simvastatin - therapeutic use - child
Treatment Outcome
Triglycerides - blood - child
Ensayo clínico, Hiperlipidemia, Simvastatina, Nefropatías, Niños
Clinical trial . Hyperlipidemia . Simvastatin . Nephropathies. Children
Descripción : Children with hyperlipidemia secondary to renal disease develop premature atherosclerosis and glomerulosclerosis. The aims of this pilot study were to find the dosage and short-term efficacy of simvastatin and potential adverse events in children with chronic kidney diseases. This was a random, double-blind, placebo-controlled, cross-over clinical trial performed on children with hyperlipidemia secondary to kidney disorders. After being placed on a diet for 3 months, patients were randomly placed in one of two balanced group blocks and treated with diet plus placebo or simvastatin at doses of 5 mg for children weighing 30 kg or less and 10 mg for children weighing over 30 kg, for 1 month, and then doubled for two more months. After this treatment, patients were placed on a diet for a 3-month washout period. During the last trial phase, patients previously treated with simvastatin were administered a placebo, and vice versa. A total of 25 patients with ages ranging from 4 years to 17 years were included in the study. A significant decrease in the levels of serum cholesterol (26.4%), low-density lipoprotein (LDL) (35.4%) and triglycerides (23.1%) was noted during the study, primarily during the simvastatin treatments, in which case cholesterol, LDL and triglycerides decreased by 23.3%, 33.7% and 21%, respectively. High-density lipoprotein (HDL) levels increased moderately (10.7%) during the study but without differences during simvastatin treatment. No differences were found across groups with respect to adverse events. In the short-term the combination of diet and simvastatin was effective in lowering hyperlipidemia in children with renal disorders. © IPNA 2009.
Colaborador(es) u otros Autores: Arredondo-García JL
Gutiérrez-Castrellón P
Bojorquez-Ochoa A
Maya ER
Pérez-Martínez Mdel P
Fecha de publicación : 2009
Tipo de publicación: Artículo
Formato: pdf
Identificador del Recurso : 10.1007/s00467-009-1128-7
Fuente: Pediatric Nephrology 24(6):1205 - 1210
URI : http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2388
Idioma: eng
Aparece en las colecciones: Artículos

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.